ABSTRACT OBJECTIVE: This article's objective is to critically assess the Bulgarian legislation on health technology assessment (HTA). It analyses how innovative therapies and orphan drugs in particular would respond to the regulators' decision-making criteria for reimbursement.
INTRODUCTION
Greater public awareness of health care rationing decisions and growing consumerist position on health care policy require more accountability, transparency and legitimacy in the decision-making process. Decision-makers need a more comprehensive approach to set priorities and obtain maximum benefi t from limited resources, without compromising the ethical and social values underpinning health systems. 1 Bulgaria has only recently started offi cially implementing these ideas in reimbursement decisiontaking and the country still lacks experience and expertise. Nevertheless, economic and societal realities obligate a strategic approach to health technology assessment (HTA) concepts. In Bulgaria, the
Ordinance for regulation and registration of prices of medicinal products, conditions, procedures and criteria for inclusion, amendments and/or exclusion of medicinal products from the Positive Drug List (PDL) and the terms and conditions for work of the Drug Pricing and Reimbursement Committee
has been considerably amended to provide a more sophisticated and more effi cient base for reimbursement decisions. 2 This piece of legislation is the fi rst real HTA step in Bulgaria. This article's objective is to critically assess the methodological quality of the Bulgarian legislation on HTA. It analyses how innovative therapies and orphan drugs in particular would respond to the new regulation's decision-making criteria for reimbursement. Finally, the study draws policy recommendations to optimise the reimbursement decision-making criteria in Bulgaria.
MATERIALS AND METHODS
The research methodology consists of two parts. The fi rst is a critical analysis of the current decisionmaking criteria for drug reimbursement in Bulgaria. The second is a hypothetical scenario planning that theoretically explores how this new mechanism would work in practice for the so called orphan medicinal products. Orphan drugs' legal defi nition by Regulation (EC) No 141/2000 of 16 December 1999 was used for the purposes of this study. 3 Three different scenarios ("pessimistic", "optimistic" and "realistic") were constructed following generally accepted principles and guidelines. 4 The most signifi cant orphan drug-related variables were used, so the three scenarios could exemplify real-life forecasting environments. Nevertheless, because of their judgmental nature, the proposed scenarios are a conceptual description of a plausible future, emphasising the underlying reasoning as well as sources of uncertainty 5 , rather than a fi rm forecast.
RESULTS

REVIEW OF THE NEW HTA LEGISLATION IN BULGARIA
HTA has practically no record in Bulgaria. The only relevant legal provision in this fi eld is the already mentioned Ordinance. The latest signifi cant amendments in it were motivated by the offi cials' desire to improve decision-making effi ciency in the context of increasing health care expenditures. The approval for inclusion into PDL (which is a must for subsequent reimbursement by public funds) was reorganised into an assessment scoring system (Table  1) with an explicit threshold to be met.
ORPHAN DRUGS' SCENARIOS
As reimbursement decisions in Bulgaria are not publicly justifi ed, stakeholders are not aware of the real reasons why a medicinal product is accepted/ not accepted for inclusion in PDL. A hypothetical new orphan drug has been fi ltered through the Bulgarian HTA's legal criteria, producing three different scenarios (Table 1 ) with the following critical outcomes:
• Therapeutic alternative (optimistic 20 points out of a 20-point maximum): by defi nition the orphan designation means that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question or, if such a method exists, that the medicinal product is of signifi cant benefi t to those affected by that condition. 3 Nevertheless, the pessimistic scenario scored no points here, as the current defi nition of therapeutic alternative in the Ordinance is too broad and ambiguous.
• Clinical effectiveness (optimistic 28 points out of a 45-point maximum): this criterion is probably the most diffi cult to apply. The uncertainty is demonstrated by the large amplitude of the clinical effectiveness score under the different scenarios. This is a direct consequence of the relative lack of clinical evidence about orphan drugs' cost-effectiveness. 6 It is a usual situation that, at the time of product launch, there may not be the same breadth and quality of clinical evidence for orphan drugs, compared with those for more common diseases. 7 Estimations for the middle-of-the-road scenario Estimations for the middle-of-the-road scenario assumed that the European Medicines Agency's assumed that the European Medicines Agency's (EMA) market authorisation of orphan drugs (EMA) market authorisation of orphan drugs would be regarded as a clear sign for the orphan would be regarded as a clear sign for the orphan drugs' added value and benefi ts to patients. If a drugs' added value and benefi ts to patients. If a new product represents a new therapeutic group new product represents a new therapeutic group itself, its effi cacy usually should be considered itself, its effi cacy usually should be considered implicitly without much debate until enough realimplicitly without much debate until enough realworld data are collected. The main focus of the world data are collected. The main focus of the initial clinical effectiveness evaluation should be initial clinical effectiveness evaluation should be the extent by which the new product responds to the extent by which the new product responds to unmet health needs. unmet health needs. 8 8 • Safety (optimistic 12 points out of a 30-point maximum): all considerations here are based on the well applied rule that medicinal products must have an acceptable safety profi le in order to be approved for use.
• Pharmacoeconomics (optimistic 0 points out of a 40-point maximum): because of the high price and the relative small number of rare diseases patients, it is impossible for orphan medicinal products to meet the standard cost-effectiveness criteria. 7 These products are indicated for medical conditions, which are most often chronic, severely disabling, and/or life-threatening, potentially requiring a life-long use of orphan medicinal therapy.
• Treatment of socially high-risk conditions (optimistic 0 points out of a 20-point maximum): to be considered a socially high risk in Bulgaria, a disorder should meet a combination of certain criteria (high mortality and morbidity; high share of Under the currently defined reimbursement decision-making criteria a hypothetical middle-ofthe-road scenario planning shows that an orphan drug would score a total of 60 points, thus making the fi nal outcome of real-life assessment and decisionmaking heavily dependent on small fl uctuations.
DISCUSSION
New HTA regulation in Bulgaria and its explicit criteria are a step toward more objectiveness in the reimbursement decision-making process. However, this framework needs to be further refi ned and completed with precise defi nitions and methodological guidelines. This simple scenario planning shows that the relative weight of different scoring criteria may be too generalised and subsequently favours generic medicinal products over new ones, conventional therapies over innovative ones. It is reasonable to assess innovative pharmaceuticals from a different perspective. For example, Canada has a separate review process for making cancer drug funding recommendations. 9 Recent studies also conclude that personalised medicine technologies do not neatly fi t into existing health technology assessment and reimbursement processes. 10 Applying a specifi c assessment and appraisal approach to orphan drugs and innovative medicines in general is justifi ed, because these products are improving outcomes for patients but at a signifi cant cost. Accessing these unfunded drugs concerns patients, challenges their physicians, and raises important policy and legal issues. 11 METHODOLOGICAL RIGOUR Several criteria are not well defi ned and may affect future decisions' consistency. The scenario planning suggests that the therapeutic alternative criterion's 20 points may be crucial to whether an orphan medicinal product is recommended for reimbursement or not. Currently, this indicator is defi ned as "there is no other medicinal therapeutic alternative for the indicated condition". Medicinal therapeutic alternative is a very broad term. Defi ning an alternative may imply clinical equivalence, recommended therapy, routinely used therapy, etc. Equivalence may be pharmacological, in vitro, in vivo, therapeutic (combination of the previous three), etc. Outcomes of such comparisons may be greatly predetermined by the choice of comparator. In Austria for example, a product is assessed from a pharmacological point of view in the context of available therapeutic alternatives including non-pharmacological treatment alternatives. It determines comparable pharmaceuticals with the same dosage (if appropriate, on ATC 4 level) already listed in the Austrian Reimbursement Code. 12 In France, when a new product belongs to a well-known therapeutic category, its effi cacy is compared with similar drugs from the same category. However, if a product represents a new therapeutic group itself, it is compared with products with the same therapeutic aim. In this case, the appraisal is more implicit, as innovative products may be the potential response to unmet health needs, which matters most in this case. 8 Missing offi cially accepted and disclosed methodology for HTA is another weak point. In many countries, regulators have published HTA guidelines to outline the methodological requirements for manufacturers and reviewers. In Germany for example, for new products with orphan drug status, a simplifi ed submission process applies. The manufacturer has to submit an extract of the dossier and the regulatory agency only decides on the level of additional benefi t, as the additional benefi t in general is considered to be demonstrated by the orphan designation. This exception applies to orphan drugs as long as anticipated peak sales stay below €50 million a year. If this threshold is exceeded, a complete dossier has to be submitted by the manufacturer. 13 It is a similar situation in France, assessment decisions take into account the clinical added value of the drug (actual benefi t) and the improvement in the clinical added value of the drug as compared to existing therapies (improvement in actual benefi t). 14 Assessing generally a pharmaceutical's added value is tricky. It should be noted that orphan drugs are very often the fi rst product offering a medicinal therapy for a particular indication. In this case they could be classifi ed as a major improvement in terms of clinical effectiveness. If a treatment alternative already exists, the majority of countries perform a systematic and evidence-based evaluation of a drug's clinical and economic characteristics in comparison to the standard treatment routine. However, international experience agrees that the question if a medicine is cost-effective in relation to treatment alternatives is predominantly answered in a political and social context. 15 The lack of reliable data on all the criteria is also present. For example, there has been a growing interest in including patient reported outcomes as secondary or primary endpoints in medical research. 16 Health related quality of life (HRQOL) is considered a relevant criterion from a patient point of view. It is an effi ciency measure for evaluating the benefi ts of new and existing treatments. However, there is a variety of different methodologies and no uniform guidelines to explore HRQOL. That combination could potentially bias the review process. Furthermore, it is not clear how this information would be used and applied in Bulgaria. To assess a medicinal product's impact on HRQOL, objective data on the individual precondition HRQOL is needed. Otherwise, it is not reasonable to draw conclusions.
Budget impact's data are also missing. There is increasing recognition that a comprehensive economic assessment of a new health care intervention at the time of launch requires both a cost-effectiveness analysis and a budget impact analysis. 17 Unlike the common practice in Bulgaria, budget impact does not include only direct healthcare costs. A specifi c health-related burden includes also direct and indirect non-medical costs. The Bulgarian legislation does not provide any further details on how budget impact should be calculated and what it should include. This methodological shortcoming may leave room for controversial and suboptimal reimbursement decisions.
TRANSPARENCY AND ACCOUNTABILITY Regulators are supposed to balance societal and medical requirements against the need for certainty about benefi t and risk for new pharmaceuticals. Even in countries experienced in HTA, there is still limited public information, suggesting that the decision-making process may have been tentative. 17 A recent study by Franken at al. demonstrates that European drug reimbursement systems could greatly improve transparency of the decision-making process. 18 Researchers further detect that it is especially appraisal that is lacking transparency. Justifi cation with explicit criteria is generally limited. Although relevant criteria are similar across systems, their operationalisation varies and their role in the appraisal process is not always clear. 19 As Cleemput et al. propose further, transparency of this process can be improved by using an explicit decision framework. Systematic use of such a framework enhances consistency across decisions, allows justifi cation of value judgments, and thus enhances legitimacy of societal decision-making. 19 A presentation of the decision-making process in Germany describes such a mechanism in practice. The German Federal Joint Committee (FJC) defi nes health care elements that are to be reimbursed by sickness funds. The FJC can commission benefi t assessments. Appropriate participation of relevant parties for the commission-related development of assessments has to be ensured, as well as opportunity for comment on all important segments of the assessment procedure. Transparency of the whole process is evidenced by clear reporting of procedures and criteria in all phases undertaken in the benefi t assessment. 20 Bekkering G et al. further identify the most important means of enhancing transparency (to implement a scoping process to support the development of the research question; to separate the work of the external experts performing the evidence assessment from that of the institute formulating recommendations; to implement open peer review by publishing both the comments of the reviewers and their names). Finally, the relevant parties should have the right to appeal the fi nal decision on judicial grounds. 20 
CONCLUSIONS
It is clear that a generalised reimbursement decisionmaking framework (as the one currently used in Bulgaria) would prioritise generic medicinal products over innovative ones. Its explicit objective is cost-minimising and budget-saving. Nevertheless, common sense and fundamental values insist that people should not be denied the equal right to adequate health care. That is why decision-makers need more systematic and objective mechanisms when assessing and appraising both conventional and innovative health technologies.
It is not a question of choice in the case of rare diseases, where there is normally no etiological treatment and it is all about symptomatic and supportive therapies. Orphan drugs' mission is to provide a therapeutic alternative when one is not available at all. This is a key aspect to understand these products' value and to make proper reimbursement decisions. The availability of a therapeutic alternative emerges as a central reimbursement decision-making criterion for the orphan drugs. It should be cautiously defi ned, taking into account patients' unmet health needs.
Reimbursement decision-making needs transpar- 
